Featured Videos

SAN FRANCISCO, CA USA (UroToday.com) - In this study, previously treated patients with progressive germ cell tumors (GCT) were eligible if they had not received or were not candidates for high-dose chemotherapy (HDCT).

Treatment was every 2 weeks in 6-week cycles, and the primary endpoint was response rate. Patients on arm one received flavopiridol 70mg/m2 plus oxaliplatin 85mg/m2, and patients in arm 2 (flavopiridol + FOLFOX) tested identical doses of flavopiridol and oxaliplatin plus 5-FU (400mg/m2 bolus, then 1800mg/m2 over 48 hours) and leucovorin (LV) 400mg/m2.

Agucancerssympalt thumb total of 36 patients (7 arm 1, 29 arm 2) were enrolled in the study, and of those, 33 had non-seminoma. Twenty -even patients had primary testis and 7 had primary mediastinum tumors. Twenty-two patients had received prior HDCT and 13 had LR (> 2 years), including 2 on arm 1 and 11 on arm 2. Since there was no response in arm 1 (0/7 patients), this arm was closed early. Of 25 evaluable patients on arm 1, 6 achieved a PR, 9 had SD, and 10 had PD. Five out of 10 evaluable LR patients on arm 1 had a PR, including one pathologic CR, one PR-negative markers who received radiation (RT) to a residual bone metastasis, and 1 PR-positive markers who received RT to a residual nodal mass. These 3 patients remain disease-free ≥ 19 months post-chemotherapy and ≥ 17months post-RT or surgery. Median progression-free survival and overall survival were 2.3 months and 7.3 months for all patients, respectively, and 3.2 months and 11.2 months for patients in arm 2.

The important take-home point of this phase 2 study is that, although neither arm met the hypothesized endpoint, flavopiridol plus FOLFOX was particularly active in later relapse patients, with approximately a 50% overall RR. Further studies are certainly needed to evaluate the use of FOLFOX, with or without flavopiridol, in late-relapse patients.

Highlights of a presentation by Darren Richard Feldman at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Memorial Sloan Kettering Cancer Center, New York, NY USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

View Full 2014 GU Cancers Symposium Coverage




Clinical Trials
Searchable data base of currently enrolling clinical trials
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 2

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.


Upcoming educational events
November 23-25, 2018 / European Society for Medical Oncology Asia 2018 Congress
European Society for Medical Oncology Asia 2018 Congress
November 25-30, 2018 / RSNA 2018 Annual Meeting
RSNA 2018 Annual Meeting